A prospective surveillance study of candidaemia: epidemiology, risk factors, antifungal treatment and outcome in hospitalized patients

Ranjith Rajendran, Leighann Sherry, Ashutosh Deshpande, Elizabeth M. Johnson, Mary F. Hanson, Craig Williams, Carol A Munro, Brian L. Jones, Gordon Ramage

Research output: Contribution to journalArticle

Abstract

This study provide an up-to-date overview of the epidemiology and risk factors for Candida bloodstream infection in Scotland in 2012/2013, and the antifungal susceptibility of isolates from blood cultures from 11 National Health Service boards within Scotland. Candida isolates were identified by chromogenic agar and confirmed by MALDI-TOF methods. Survival and associated risk factors for patients stratified as albicans and non-albicans cases were assessed. Information on the spectrum of antifungals used was collected and summarized. The isolates sensitivity to different antifungals was tested by broth microdilution method and interpreted according to CLSI/EUCAST guidelines. Forty one percent of candidaemia cases were associated with Candida albicans, followed by C. glabrata (35%), C. parapsilosis (11.5%), and remainder with other Candida spp. C. albicans and C. glabrata infections were associated with 20.9 and 16.3% mortality, respectively. Survival of patients with C. albicans was significantly lower compared to non-C. albicans and catheter line removal in C. albicans patients significantly increases the survival days. Predisposing factors such as total parenteral nutrition, and number of days on mechanical ventilation or in intensive care, were significantly associated with C. albicans infections. Fluconazole was used extensively (64.5%) for treating candidaemia cases followed by echinocandins (33.8%). Based on CLSI breakpoints, MIC test found no resistance to any antifungals tested except 5.26% fluconazole resistance among C. glabrata isolates. Moreover, by comparing to EUCAST breakpoints we found 3.95% of C. glabrata isolates were resistant to anidulafungin. We have observed a shift in Candida spp. with an increasing isolation of C. glabrata. Delay and choice of antifungal treatment are associated with poor clinical outcomes.
Original languageEnglish
Pages (from-to)915
JournalFrontiers in Microbiology
DOIs
Publication statusPublished - 16 Jun 2016

Fingerprint

Candidemia
Candida albicans
Epidemiology
Candida
Prospective Studies
Fluconazole
Scotland
anidulafungin
Survival
Infection
Echinocandins
Total Parenteral Nutrition
Matrix-Assisted Laser Desorption-Ionization Mass Spectrometry
National Health Programs
Critical Care
Artificial Respiration
Causality
Agar
Catheters
Guidelines

Cite this

Rajendran, Ranjith ; Sherry, Leighann ; Deshpande, Ashutosh ; Johnson, Elizabeth M. ; Hanson, Mary F. ; Williams, Craig ; Munro, Carol A ; Jones, Brian L. ; Ramage, Gordon. / A prospective surveillance study of candidaemia : epidemiology, risk factors, antifungal treatment and outcome in hospitalized patients. In: Frontiers in Microbiology. 2016 ; pp. 915.
@article{604dcd63a4464b5683b33ecef1e2c502,
title = "A prospective surveillance study of candidaemia: epidemiology, risk factors, antifungal treatment and outcome in hospitalized patients",
abstract = "This study provide an up-to-date overview of the epidemiology and risk factors for Candida bloodstream infection in Scotland in 2012/2013, and the antifungal susceptibility of isolates from blood cultures from 11 National Health Service boards within Scotland. Candida isolates were identified by chromogenic agar and confirmed by MALDI-TOF methods. Survival and associated risk factors for patients stratified as albicans and non-albicans cases were assessed. Information on the spectrum of antifungals used was collected and summarized. The isolates sensitivity to different antifungals was tested by broth microdilution method and interpreted according to CLSI/EUCAST guidelines. Forty one percent of candidaemia cases were associated with Candida albicans, followed by C. glabrata (35{\%}), C. parapsilosis (11.5{\%}), and remainder with other Candida spp. C. albicans and C. glabrata infections were associated with 20.9 and 16.3{\%} mortality, respectively. Survival of patients with C. albicans was significantly lower compared to non-C. albicans and catheter line removal in C. albicans patients significantly increases the survival days. Predisposing factors such as total parenteral nutrition, and number of days on mechanical ventilation or in intensive care, were significantly associated with C. albicans infections. Fluconazole was used extensively (64.5{\%}) for treating candidaemia cases followed by echinocandins (33.8{\%}). Based on CLSI breakpoints, MIC test found no resistance to any antifungals tested except 5.26{\%} fluconazole resistance among C. glabrata isolates. Moreover, by comparing to EUCAST breakpoints we found 3.95{\%} of C. glabrata isolates were resistant to anidulafungin. We have observed a shift in Candida spp. with an increasing isolation of C. glabrata. Delay and choice of antifungal treatment are associated with poor clinical outcomes.",
author = "Ranjith Rajendran and Leighann Sherry and Ashutosh Deshpande and Johnson, {Elizabeth M.} and Hanson, {Mary F.} and Craig Williams and Munro, {Carol A} and Jones, {Brian L.} and Gordon Ramage",
year = "2016",
month = "6",
day = "16",
doi = "10.3389/fmicb.2016.00915",
language = "English",
pages = "915",
journal = "Frontiers in Microbiology",
issn = "1664-302X",
publisher = "Frontiers Media",

}

A prospective surveillance study of candidaemia : epidemiology, risk factors, antifungal treatment and outcome in hospitalized patients. / Rajendran, Ranjith; Sherry, Leighann; Deshpande, Ashutosh; Johnson, Elizabeth M. ; Hanson, Mary F. ; Williams, Craig; Munro, Carol A; Jones, Brian L. ; Ramage, Gordon.

In: Frontiers in Microbiology, 16.06.2016, p. 915.

Research output: Contribution to journalArticle

TY - JOUR

T1 - A prospective surveillance study of candidaemia

T2 - epidemiology, risk factors, antifungal treatment and outcome in hospitalized patients

AU - Rajendran, Ranjith

AU - Sherry, Leighann

AU - Deshpande, Ashutosh

AU - Johnson, Elizabeth M.

AU - Hanson, Mary F.

AU - Williams, Craig

AU - Munro, Carol A

AU - Jones, Brian L.

AU - Ramage, Gordon

PY - 2016/6/16

Y1 - 2016/6/16

N2 - This study provide an up-to-date overview of the epidemiology and risk factors for Candida bloodstream infection in Scotland in 2012/2013, and the antifungal susceptibility of isolates from blood cultures from 11 National Health Service boards within Scotland. Candida isolates were identified by chromogenic agar and confirmed by MALDI-TOF methods. Survival and associated risk factors for patients stratified as albicans and non-albicans cases were assessed. Information on the spectrum of antifungals used was collected and summarized. The isolates sensitivity to different antifungals was tested by broth microdilution method and interpreted according to CLSI/EUCAST guidelines. Forty one percent of candidaemia cases were associated with Candida albicans, followed by C. glabrata (35%), C. parapsilosis (11.5%), and remainder with other Candida spp. C. albicans and C. glabrata infections were associated with 20.9 and 16.3% mortality, respectively. Survival of patients with C. albicans was significantly lower compared to non-C. albicans and catheter line removal in C. albicans patients significantly increases the survival days. Predisposing factors such as total parenteral nutrition, and number of days on mechanical ventilation or in intensive care, were significantly associated with C. albicans infections. Fluconazole was used extensively (64.5%) for treating candidaemia cases followed by echinocandins (33.8%). Based on CLSI breakpoints, MIC test found no resistance to any antifungals tested except 5.26% fluconazole resistance among C. glabrata isolates. Moreover, by comparing to EUCAST breakpoints we found 3.95% of C. glabrata isolates were resistant to anidulafungin. We have observed a shift in Candida spp. with an increasing isolation of C. glabrata. Delay and choice of antifungal treatment are associated with poor clinical outcomes.

AB - This study provide an up-to-date overview of the epidemiology and risk factors for Candida bloodstream infection in Scotland in 2012/2013, and the antifungal susceptibility of isolates from blood cultures from 11 National Health Service boards within Scotland. Candida isolates were identified by chromogenic agar and confirmed by MALDI-TOF methods. Survival and associated risk factors for patients stratified as albicans and non-albicans cases were assessed. Information on the spectrum of antifungals used was collected and summarized. The isolates sensitivity to different antifungals was tested by broth microdilution method and interpreted according to CLSI/EUCAST guidelines. Forty one percent of candidaemia cases were associated with Candida albicans, followed by C. glabrata (35%), C. parapsilosis (11.5%), and remainder with other Candida spp. C. albicans and C. glabrata infections were associated with 20.9 and 16.3% mortality, respectively. Survival of patients with C. albicans was significantly lower compared to non-C. albicans and catheter line removal in C. albicans patients significantly increases the survival days. Predisposing factors such as total parenteral nutrition, and number of days on mechanical ventilation or in intensive care, were significantly associated with C. albicans infections. Fluconazole was used extensively (64.5%) for treating candidaemia cases followed by echinocandins (33.8%). Based on CLSI breakpoints, MIC test found no resistance to any antifungals tested except 5.26% fluconazole resistance among C. glabrata isolates. Moreover, by comparing to EUCAST breakpoints we found 3.95% of C. glabrata isolates were resistant to anidulafungin. We have observed a shift in Candida spp. with an increasing isolation of C. glabrata. Delay and choice of antifungal treatment are associated with poor clinical outcomes.

U2 - 10.3389/fmicb.2016.00915

DO - 10.3389/fmicb.2016.00915

M3 - Article

SP - 915

JO - Frontiers in Microbiology

JF - Frontiers in Microbiology

SN - 1664-302X

ER -